Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 71.33% | 59.33% | 56.56% | 27.11% | 29.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 95.95% | 72.29% | 42.33% | -5.55% | -8.50% |
| Operating Income | -95.95% | -72.29% | -42.33% | 5.55% | 8.50% |
| Income Before Tax | -72.88% | -68.71% | -49.89% | -2.17% | -4.84% |
| Income Tax Expenses | 439.22% | 7,650.00% | 961.11% | -73.63% | -71.98% |
| Earnings from Continuing Operations | -73.01% | -68.82% | -49.96% | -2.07% | -4.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -68.64% | -80.20% | -87.77% | -92.84% | -88.58% |
| Net Income | -73.41% | -69.58% | -51.26% | -4.09% | -7.25% |
| EBIT | -95.95% | -72.29% | -42.33% | 5.55% | 8.50% |
| EBITDA | -96.00% | -72.32% | -42.32% | 5.71% | 8.66% |
| EPS Basic | -15.36% | -33.72% | -29.73% | 4.24% | 8.55% |
| Normalized Basic EPS | -16.04% | -31.31% | -23.71% | 10.06% | 12.16% |
| EPS Diluted | -15.36% | -33.72% | -29.73% | 4.24% | 8.55% |
| Normalized Diluted EPS | -16.04% | -31.31% | -23.71% | 10.06% | 12.16% |
| Average Basic Shares Outstanding | 47.80% | 26.84% | 17.77% | 13.18% | 21.83% |
| Average Diluted Shares Outstanding | 47.80% | 26.84% | 17.77% | 13.18% | 21.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |